CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Ticagrelor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01919723
NCT01919723Phase 2Completed
CompareCT.gov

Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention

University of Alabama at Birmingham·interventional·Posted Aug 9, 2013·Updated Feb 28, 2017

In Brief

A Phase 2 clinical trial evaluating Ticagrelor and Eptifibatide for Acute Coronary Syndrome. Completed, enrolled 70 participants across 2 sites.

Detailed Summary

This purpose of this study is to measure platelet response to ticagrelor and eptifibatide bolus-only compared with ticagrelor and eptifibatide bolus plus 2-hour infusion administrated after cardiac catheterization in patients undergoing non-emergent percutaneous coronary intervention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 9, 2013
Enrollment StartFeb 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.9 years ago

Interventions

Ticagrelordrug

Ticagrelor loading dose

Eptifibatidedrug

i.v. infusion